UCLA Researchers & Innovators
Industry & Investors
News & Events
About
Concierge
Search Results - varghese+john
14
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Salivary Exosome (NSEV) Analysis to Elucidate Intercellular Signaling Events that Precede Pilot Fatigue (UCLA Case No. 2021-172)
Researchers at UCLA’s Department of Neurology and Drug Discovery Lab have identified a novel set of biomarkers that change based on levels of Cognitive Fatigue (CF). These biomarkers can be used to non-invasively predict and assess levels of cognitive fatigue. BACKGROUND: Cognitive fatigue (CF) is an important factor in the efficiency and safety...
Published: 7/31/2024
|
Inventor(s):
Bruce Teter
,
Samuel Whitaker Johnson-Cohn
,
Varghese John
Keywords(s):
biomarkers
,
cognitive fatigue
,
exosome
,
noninvasive
,
non-invasive
Category(s):
Diagnostic Markers > Targets And Assays
Small Molecule Humanin Mimetics and Enhancers That Normalize Neuronal p-AKT as Novel Therapeutics for Alzheimer's Disease (UCLA Case No. 2023-230)
UCLA researchers in the Department of Neurology have discovered novel small molecule humanin mimetics for the treatment of Alzheimer's disease and other chronic conditions with dysregulated p-Akt. BACKGROUND: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60-70% of all cases. Nearly 7 million Americans are living...
Published: 7/22/2024
|
Inventor(s):
Varghese John
Keywords(s):
Alzheimers disease
,
Cardiovascular
,
Cardiovascular Disease
,
Dementia
,
diabetes
,
mimetics
,
pAKT signaling
,
small molecules
Category(s):
Therapeutics > CNS and Neurology
,
Therapeutics > Cardiovascular
2021-241: Enhancers of Brain Gamma Oscillations for Treatment of Neurological Disorders
SUMMARY: UCLA researchers in the Department of Neurology have developed a novel small molecule to improve native gamma oscillations as a treatment for cognitive decline in various neurological disorders. BACKGROUND: Neural circuits are facilitated by brain oscillations or rhythmic electric activity at distinct frequencies. These frequency variations...
Published: 9/5/2023
|
Inventor(s):
Varghese John
,
Istvan Mody
,
Jesus Campagna
,
Barbara Jagodzinska
,
Xiaofei Wei
Keywords(s):
Category(s):
Therapeutics > CNS and Neurology
,
Therapeutics > Psychiatry And Mental Health
2022-177: DRUG COMBINATION TO INHIBIT BOTH MPRO AND PLPRO PROTEASES OF SARS-COV-2
SUMMARY: UCLA researchers in the Department of Neurology have developed a novel small-molecule protease inhibitor cocktail to robustly suppress COVID-19 infection. INTRODUCTION: COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Despite the development of vaccines, COVID-19 was the third-leading cause of death in the U.S. in 2021,...
Published: 9/5/2023
|
Inventor(s):
Varghese John
,
Robert Damoiseaux
,
Melody (Man Hing) Li
Keywords(s):
Category(s):
Therapeutics
,
Therapeutics > Infectious Diseases
,
Therapeutics > Infectious Diseases > COVID
2020-832: Novel Compounds Targeting APOE4 That Enhance Brain SIRT1 Levels and Target Novel Mechanism of Action
Researchers at UCLA's Drug Discovery Lab and Department of Chemistry have developed new chemical entity (NCE) analogs of A03, which together form a new class of compounds that target apolipoprotein E4 (ApoE4)-mediated deficits in the tau deacetylase enzyme, sirtuin 1 (SirT1). These NCEs provide an opportunity for novel therapeutic development in Alzheimer's...
Published: 9/5/2023
|
Inventor(s):
Varghese John
,
Jesus Campagna
,
Michael Jung
Keywords(s):
Brain
Category(s):
Therapeutics
2020-408: sAPPalpha Targeted Therapeutics for Alzheimer’s Disease
UCLA researchers from the Department of Neurology have developed a novel application of two compounds that target the upstream formation of toxic amyloid-beta oligomers for the effective treatment of Alzheimer’s disease. BACKGROUND: Alzheimer’s Disease (AD) is the most common age-related neurodegenerative disorder currently affecting ~6...
Published: 7/19/2023
|
Inventor(s):
Varghese John
,
Sujyoti Chandra
Keywords(s):
Chemical
,
Cns
,
Therapeutics & Vaccines
Category(s):
Therapeutics
,
Therapeutics > CNS and Neurology
2018-200 AMYLOID PRECURSOR PROTEIN-SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER’S DISEASE
Amyloid Precursor Protein-Selective BACE Inhibitors for Alzheimer’s DiseaseSUMMARYUCLA researchers in the Department of Neurology have invented novel Alzheimer’s disease (AD) therapeutics that are selective for BACE1 inhibition and cleavage of the amyloid precursor protein (APP) substrate.BACKGROUNDAlzheimer’s disease is characterized...
Published: 7/19/2023
|
Inventor(s):
Barbara Jagodzinska
,
Varghese John
,
Patricia Spilman
,
Jesus Campagna
Keywords(s):
Cns
,
Life Science Research Tools
,
Medical Devices and Materials
,
Targets And Assays
,
Therapeutics & Vaccines
Category(s):
Life Science Research Tools
,
Diagnostic Markers > Targets And Assays
,
Medical Devices
,
Therapeutics
,
Therapeutics > CNS and Neurology
2019-231: Radiotracer for Synaptic Imaging
UCLA researchers in the Department of Neurology have synthesized a novel radiotracer that selectively identifies functional synapses for monitoring of synaptic loss in Alzheimer’s patients. BACKGROUND: Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder that cannot be prevented, cured or slowed. It affects more than 17...
Published: 7/19/2023
|
Inventor(s):
Varghese John
,
Mohammad Parvez Alam
,
Asa Hatami
,
Daniel Silverman
,
Saman Sadeghi
Keywords(s):
Cns
,
Diagnostic Markers & Platforms
,
Medical Imaging
,
PET
Category(s):
Medical Devices > Medical Imaging > PET
Identification and Development of Dual nSMase2-AChE Inhibitors for Neurodegenerative Disorders (UCLA Case No. 2019-279)
UCLA researchers in the Department of Neurology, and the Department of Chemistry & Biochemistry have developed small molecule inhibitors of both the neutral sphingomyelinase 2 (nSMase2) and acetylcholinesterase (AChE) as novel therapeutics for neurodegenerative disorders caused by protein aggregation. BACKGROUND: Neurodegenerative diseases such...
Published: 10/24/2024
|
Inventor(s):
Varghese John
,
Neil Garg
Keywords(s):
Cns
,
Therapeutics & Vaccines
Category(s):
Therapeutics
,
Therapeutics > CNS and Neurology
2018-028 PATHWAY-DEPENDENT INHIBITION OF PROTEOPATHIC SEED TRANSMISSION
Pathway-Dependent Inhibition Of Proteopathic Seed TransmissionSUMMARYUCLA researchers in the Department of Neurology have developed a novel approach to stop the propagation of proteopathic diseases, which could be applied to wide range of neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease.BACKGROUNDProteopathy...
Published: 7/19/2023
|
Inventor(s):
Neil Garg
,
Varghese John
,
Kanagasabai Vadivel
,
Barbara Jagodzinska
,
Tina Bilousova
Keywords(s):
Cns
,
Life Science Research Tools
,
Targets And Assays
,
Therapeutics & Vaccines
Category(s):
Life Science Research Tools
,
Diagnostic Markers > Targets And Assays
,
Therapeutics
,
Therapeutics > CNS and Neurology
1
2